keyword
MENU ▼
Read by QxMD icon Read
search

childhood acute lymphoblastic leukemia

keyword
https://www.readbyqxmd.com/read/29160610/do-pregnancy-characteristics-contribute-to-rising-childhood-cancer-incidence-rates-in-the-united-states
#1
Rebecca D Kehm, Theresa L Osypuk, Jenny N Poynter, David M Vock, Logan G Spector
BACKGROUND: Since 1975, childhood cancer incidence rates have gradually increased in the United States; however, few studies have conducted analyses across time to unpack this temporal rise. The aim of this study was to test the hypothesis that increasing cancer incidence rates are due to secular trends in pregnancy characteristics that are established risk factors for childhood cancer incidence including older maternal age, higher birthweight, and lower birth order. We also considered temporal trends in sociodemographic characteristics including race/ethnicity and poverty...
November 21, 2017: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/29153092/is-intrachromosomal-amplification-of-chromosome-21-iamp21-always-intrachromosomal
#2
Karen D Tsuchiya, Billy Davis, Rebecca A Gardner
Recurrent chromosomal abnormalities in childhood B-cell acute lymphoblastic leukemia (B-ALL) provide prognostic information that is useful in determining treatment stratification. iAMP21 is a more recently recognized cytogenetic entity of B-ALL that was originally described as multiple copies of the RUNX1 gene on a structurally abnormal chromosome 21. Subsequent studies elucidated a common region of highest-level amplification that includes RUNX1. Fluorescence in situ hybridization (FISH) is the most common method used to identify iAMP21, which is defined as the presence of five or more total copies of RUNX1, with three or more extra RUNX1 signals on a single abnormal chromosome 21...
December 2017: Cancer Genetics
https://www.readbyqxmd.com/read/29149251/parental-age-and-risk-of-lymphoid-neoplasms
#3
Gunnar Larfors, Ingrid Glimelius, Sandra Eloranta, Karin E Smedby
High parental age at childbirth has repeatedly been linked to childhood malignancies, while few studies have focused on the offspring's risk of adult cancer. In this population-based case-control study, we identified 32,000 patients with lymphoid neoplasms, diagnosed at ages 0-79 years during the period 1987-2011, and 160,000 matched controls in Sweden. Using prospectively registered data on their first-degree relatives, we evaluated the impact of parental age on the risk of lymphoid neoplasms by subtype. Overall, each 5-year increment in maternal age was associated with a 3% increase in incidence of offspring lymphoid neoplasms (hazard ratio = 1...
November 15, 2017: American Journal of Epidemiology
https://www.readbyqxmd.com/read/29148893/reduced-intensity-delayed-intensification-in-standard-risk-pediatric-acute-lymphoblastic-leukemia-defined-by-undetectable-minimal-residual-disease-results-of-an-international-randomized-trial-aieop-bfm-all-2000
#4
Martin Schrappe, Kirsten Bleckmann, Martin Zimmermann, Andrea Biondi, Anja Möricke, Franco Locatelli, Gunnar Cario, Carmelo Rizzari, Andishe Attarbaschi, Maria Grazia Valsecchi, Claus R Bartram, Elena Barisone, Felix Niggli, Charlotte Niemeyer, Anna Maria Testi, Georg Mann, Ottavio Ziino, Beat Schäfer, Renate Panzer-Grümayer, Rita Beier, Rosanna Parasole, Gudrun Göhring, Wolf-Dieter Ludwig, Fiorina Casale, Paul-Gerhardt Schlegel, Giuseppe Basso, Valentino Conter
Purpose Delayed intensification (DI) is an integral part of treatment of childhood acute lymphoblastic leukemia (ALL), but it is associated with relevant toxicity. Therefore, standard-risk patients of trial AIEOP-BFM ALL 2000 (Combination Chemotherapy Based on Risk of Relapse in Treating Young Patients With ALL) were investigated with the specific aim to reduce treatment intensity. Patients and Methods Between July 2000 and July 2006, 1,164 patients (1 to 17 years of age) with standard-risk ALL (defined as the absence of high-risk cytogenetics and undetectable minimal residual disease on days 33 and 78) were randomly assigned to either experimental reduced-intensity DI (protocol III; P-III) or standard DI (protocol II; P-II)...
November 17, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29143289/agents-in-development-for-childhood-acute-lymphoblastic-leukemia
#5
REVIEW
Kelly W Maloney, Lia Gore
Acute lymphoblastic leukemia (ALL) is the most common cancer in childhood. Standard chemotherapy has afforded outstanding outcomes for many patients; however, there remain some sub-groups with high-risk features, refractory disease, and patients that  relapse who have a poor prognosis with conventional treatments. Over the past decade, there have been significant advances in newer treatment options, including improved monoclonal antibody therapies, T cell engagers, and chimeric antigen T-cell receptor products, all of which have changed the landscape for patients who relapse...
November 15, 2017: Paediatric Drugs
https://www.readbyqxmd.com/read/29132473/-progress-in-clinical-studies-of-chimeric-antigen-receptor-engineered-t-cells-for-treatment-of-childhood-cancer
#6
Ya-Ru Ni, Xiao-Jun Xu, Yong-Min Tang
Nowadays, the 5-year survival rate of childhood cancer patients can be more than 80%, but some patients with relapse and refractory cancers have shown no good response to traditional strategies. Chimeric antigen receptor engineered T (CAR-T) cell therapy is promising for these patients. CAR-T cells recognize the tumor-associated antigens in a non-major histocompatibility complex-restricted manner, so their anti-tumor ability is enhanced. There are four generations of CAR-T cells now. The complete remission rate of pediatric patients with relapse and refractory acute lymphoblastic leukemia can be as high as 90% when treated with CD19-targeting CAR-T cells...
November 2017: Zhongguo Dang Dai Er Ke za Zhi, Chinese Journal of Contemporary Pediatrics
https://www.readbyqxmd.com/read/29132472/-research-progress-in-ph-like-childhood-acute-lymphoblastic-leukemia
#7
Xue Tang, Xia Guo
Philadelphia chromosome-like acute lymphoblastic leukemia (Ph-like ALL) is a subtype of B-lineage ALL (B-ALL) that displays a gene expression profile (GEP) similar to Philadelphia chromosome-positive ALL (Ph(+) ALL). It has a diverse range of genetic alterations that activate cytokine receptor genes and kinase signaling pathways, frequently accompanied by abnormal transcription factors related to lymphatic development. Children with Ph-like ALL account for 15% of children with high-risk B-ALL. It has adverse clinical features and a poor prognosis...
November 2017: Zhongguo Dang Dai Er Ke za Zhi, Chinese Journal of Contemporary Pediatrics
https://www.readbyqxmd.com/read/29127946/seasonal-trends-of-diagnosis-of-childhood-malignant-diseases-and-viral-prevalence-in-south-korea
#8
Kyu Seok Shim, Min Hyung Kim, Choong Nam Shim, Minkyu Han, In Seok Lim, Soo Ahn Chae, Sin Weon Yun, Na Mi Lee, Dae Yong Yi, Hyery Kim
BACKGROUND: Several studies have reported a seasonal trend in the diagnosis of childhood cancer suggesting seasonal factors such as infection. The present study aimed to analyze the diagnosis pattern of childhood malignant diseases using public health data, and to compare this pattern with seasonal viral infection trends. METHOD: Using the open data source of the Health Insurance Review and Assessment Service, we extracted data regarding all patients under 21 years of age and who had any cancer, aplastic anemia or myelodysplastic syndrome between September 2009 and December 2013...
November 8, 2017: Cancer Epidemiology
https://www.readbyqxmd.com/read/29126409/genomic-determinants-of-long-term-cardiometabolic-complications-in-childhood-acute-lymphoblastic-leukemia-survivors
#9
Jade England, Simon Drouin, Patrick Beaulieu, Pascal St-Onge, Maja Krajinovic, Caroline Laverdière, Emile Levy, Valérie Marcil, Daniel Sinnett
BACKGROUND: While cure rates for childhood acute lymphoblastic leukemia (cALL) now exceed 80%, over 60% of survivors will face treatment-related long-term sequelae, including cardiometabolic complications such as obesity, insulin resistance, dyslipidemia and hypertension. Although genetic susceptibility contributes to the development of these problems, there are very few studies that have so far addressed this issue in a cALL survivorship context. METHODS: In this study, we aimed at evaluating the associations between common and rare genetic variants and long-term cardiometabolic complications in survivors of cALL...
November 10, 2017: BMC Cancer
https://www.readbyqxmd.com/read/29121606/pattern-of-hematological-malignancies-in-adolescents-and-young-adults-in-bangladesh
#10
Md Mahbub Hasan, Enayetur Raheem, Tanvira Afroze Sultana, Mohammad Sorowar Hossain
INTRODUCTION: The adolescent and young adult (AYA) age group (15-39 years) bears distinct characteristics in terms of cancer biology, long-term health and treatment-related complications and psychosocial aspects. The overall scenario of cancer including hematological malignancies (HMs) is largely unknown in Bangladesh, where a significant proportion of people (44% of total population) belong to AYA age group. This study aims to describe the patterns of HM among AYA in the context of Bangladesh METHODS: Two previously published datasets (on hematological malignancies and childhood and adolescent cancer) were merged to construct a comprehensive dataset focusing exclusively on HMs in AYA age group...
November 6, 2017: Cancer Epidemiology
https://www.readbyqxmd.com/read/29113332/lncrnas-downregulated-in-childhood-acute-lymphoblastic-leukemia-modulate-apoptosis-cell-migration-and-dna-damage-response
#11
Romain Gioia, Simon Drouin, Manon Ouimet, Maxime Caron, Pascal St-Onge, Chantal Richer, Daniel Sinnett
Childhood acute lymphoblastic leukemia (cALL) accounts for 25% of pediatric cancers and is one of the leading causes of disease-related death in children. Although long non-coding RNAs (lncRNAs) have been implicated in cALL etiology, progression, and treatment response, little is known about their exact functional role. We had previously sequenced the whole transcriptome of 56 cALL patients and identified lncRNA transcripts specifically silenced in tumoral cells. Here we investigated the impact of restoring the expression of three of these (RP11-624C23...
October 6, 2017: Oncotarget
https://www.readbyqxmd.com/read/29102926/the-contribution-of-mmp-8-promoter-genotypes-to-childhood-leukemia
#12
Jen-Sheng Pei, Wen-Shin Chang, Pei-Chen Hsu, Yi-Wen Hung, Shun-Ping Cheng, Chia-Wen Tsai, DA-Tian Bau, Chi-Li Gong
BACKGROUND/AIM: Accumulated evidence has supported the notion that matrix metalloproteinase (MMP) genotypes are associated with the susceptibility of many types of cancers. However, few reports have studied the contribution of MMP genotypes to either diagnostic or prognostic potential in non-solid tumors such as leukemia. In this study, we firstly investigated the contribution of a polymorphism in the promoter region of MMP-8 (-799C/T) and two non-synonymous polymorphisms (Val436Ala and Lys460Thr) to childhood leukemia...
November 2017: In Vivo
https://www.readbyqxmd.com/read/29095311/the-relationship-between-iron-bone-marrow-stores-and-response-to-treatment-in-pediatric-acute-lymphoblastic-leukemia
#13
Alireza Moafi, Mozhdeh Ziaie, Marjan Abedi, Soheila Rahgozar, Nahid Reisi, Pardis Nematollahi, Hadi Moafi
Iron is an intracellular element whose accumulation in the body is associated with tissue damage. This study examines the effect of iron on pediatric acute lymphoblastic leukemia (ALL) and its "response to treatment." At the end of the first year of treatment, bone marrow iron store (BMIS) was evaluated in children with ALL and the relationship between iron store and minimal residual disease was investigated. Moreover, the 3-year disease-free survival (3-DFS) of patients was determined. Patients' BMIS were compared with that of subjects with normal bone marrow...
November 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29079599/predictive-value-of-mrd-in-ph-all-treated-with-imatinib-in-the-esphall-study-based-on-ig-tr-and-bcr-abl1-methodologies
#14
Giovanni Cazzaniga, Paola De Lorenzo, Julia Alten, Silja Röttgers, Jeremy Hancock, Vaskar Saha, Anders Castor, Hans O Madsen, Virginie Gandemer, Hélène Cavé, Veronica Leoni, Rolf Köhler, Giulia M Ferrari, Kirsten Bleckmann, Rob Pieters, Vincent Van der Velden, Jan Stary, Jan Zuna, Gabriele Escheric, Udo Zur Stadt, Maurizio Aricò, Valentino Conter, Martin Schrappe, Maria Grazia Valsecchi, Andrea Biondi
The prognostic value of Minimal Residual Disease in Ph+ childhood acute lymphoblastic leukemia treated with tyrosine kinase inhibitors is not fully established. We detected MRD by RQ-PCR of rearranged immunoglobulin/T-cell receptor genes and/or BCR/ABL1 fusion transcript to investigate its predictive value in patients receiving BFM high risk therapy and post induction intermittent imatinib (EsPhALL study). MRD was monitored after induction (TP1), consolidation Phase IB (TP2), HR Blocks, reinductions, end of therapy...
October 27, 2017: Haematologica
https://www.readbyqxmd.com/read/29075062/antiproliferative-and-apoptosis-inducing-activities-of-thymoquinone-in-lymphoblastic-leukemia-cell-line
#15
Amin Soltani, Batoul Pourgheysari, Hedayatollah Shirzad, Zahra Sourani
Acute lymphoblastic leukemia is one of the malignant proliferations of lymphoid cells in the early stages of differentiation and accounts for about 80% of all cases of childhood leukemia. Side effects of available treatment are still main concern. Thymoquinone (TQ), a natural compound isolated from Nigella sativa, induces growth inhibition and apoptosis in several cancer cell lines. The aim of the present study was to investigate the effect of TQ alone and in combination with doxorubicine on the proliferation inhibition and apoptosis induction of TQ in a lymphoblastic leukemia cell line...
December 2017: Indian Journal of Hematology & Blood Transfusion
https://www.readbyqxmd.com/read/29070107/-clinical-analysis-of-7-children-with-mature-b-cell-acute-lymphoblastic-leukemia
#16
Jun Wang, Qin Lu, Lu-Lu He, Xiao-Yan Sun, Meng-Jiao Sun, Yong-Jun Fang
OBJECTIVE: To evaluate the efficacy of CCCG-BNHL-2015 protocol in treatment of children with mature B-cell acute lymphoblastic leukemia (mature B-ALL). METHODS: Seven pediatric patients with newly diagnosed mature B-ALL were treated by CCCG-BNHL-2015 protocol (risk group R4) in Children's Hospital of Nanjing Medical University from November 2014 to January 2017. RESULTS: The median age of patients at initial diagnosis was 7.2 years (range 4...
October 2017: Zhongguo Shi Yan Xue Ye Xue za Zhi
https://www.readbyqxmd.com/read/29051182/oncogenetic-mutations-combined-with-mrd-improve-outcome-prediction-in-pediatric-t-cell-acute-lymphoblastic-leukemia
#17
Arnaud Petit, Amélie Trinquand, Sylvie Chevret, Paola Ballerini, Jean-Michel Cayuela, Nathalie Grardel, Aurore Touzart, Benoit Brethon, Hélène Lapillonne, Claudine Schmitt, Sandrine Thouvenin, Gerard Michel, Claude Preudhomme, Jean Soulier, Judith Landman-Parker, Guy Leverger, Elizabeth Macintyre, André Baruchel, Vahid Asnafi
Risk stratification in childhood T-ALL is mainly based on minimal residual disease (MRD) quantification. Whether oncogenetic mutation profiles can improve the discrimination of MRD-defined risk categories was unknown. 220 FRALLE2000T treated patients were tested retrospectively for NOTCH1/FBXW7/RAS and PTEN alterations. Patients with N/F mutation and R/P germline (GL) were defined as oncogenetic low risk (gLoR), while N/F GL and R/P GL or mutation and N/F mutation and R/P mutation were defined as high risk (gHiR)...
October 19, 2017: Blood
https://www.readbyqxmd.com/read/29050698/which-patients-should-i-transplant-with-acute-lymphoblastic-leukemia
#18
REVIEW
Tsofia Inbar, Jacob M Rowe, Netanel A Horowitz
Allogeneic hematopoietic cell transplantation for acute lymphoblastic leukemia (ALL) offers curative therapy for patients who are in complete remission. Historically, there was great hesitation to offer this modality to patients with ALL due to the high attendant morbidity and mortality. Furthermore, the outstanding results in childhood ALL led many to believe that significant long-term survival could be achieved using chemotherapy-based regimens alone. The International ALL Study jointly conducted by ECOG and MRC completely changed perceptions indicating, surprisingly to many, that transplantation - particularly for patients at standard risk - offered a significant survival advantage...
September 2017: Best Practice & Research. Clinical Haematology
https://www.readbyqxmd.com/read/29050696/pharmacogenomics-in-acute-lymphoblastic-leukemia
#19
REVIEW
Shawn H R Lee, Jun J Yang
Pharmacogenomics is a fast-growing field of personalized medicine using a patient's genomic profile to determine drug disposition or response to drug therapy, in order to develop safer and more effective pharmacotherapy. Childhood acute lymphoblastic leukemia (ALL), being the most common malignancy in childhood, which is treated with uniform and standardized clinical trials, is remarkably poised for pharmacogenomic studies. In the last decade, unbiased genome-wide association studies have identified multiple germline risk factors that strongly modify host response to drug therapy...
September 2017: Best Practice & Research. Clinical Haematology
https://www.readbyqxmd.com/read/29050116/-correlation-study-of-blood-drug-concentration-and-nephrotoxicity-on-high-dose-methotrexate-therapy-in-suggestion-of-diagnosis-and-treatment-of-childhood-acute-lymphoblastic-leukemia-in-the-4th-revised-edition
#20
D H Cheng, H Lu, X Q Zou
Objective: To explore the influence of the 4th revised treatment recommendations in childhood acute lymphoblastic leukemia (ALL) on high dose methotrexate(HD-MTX)-induced nephrotoxicity and MTX blood concentrations. Method: The clinical data from 330 ALL children who received 1 242 courses of HD-MTX therapies from September 2012 to November 2016 was collected. The courses were divided into two groups based on the chemotherapies: original scheme group was treated with the 3rd revised regimen, and new scheme group was treated with the 4th revised regimen...
October 2, 2017: Zhonghua Er Ke za Zhi. Chinese Journal of Pediatrics
keyword
keyword
61925
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"